Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 71335-2578

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 71335-2578). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alfuzosin Fig1)

Figure 1 (Alfuzosin Fig1)
This text describes a study conducted on 8 healthy middle-aged male volunteers to compare the plasma concentration-time profiles of Alfuzosin after a single administration of Alfuzosin Hydrochloride Extended-Release Tablets 10 mg in both a fed and fasted state. The graph displays the mean Alfuzosin plasma concentration over time in ng/mL, showing differences in absorption between the two conditions.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
This text provides information about the mean change from baseline in IPSS Total Symptom Score in Trial 1, involving the comparison between Placebo (H=167) and Alfuzosin Hydrochloride (H=170) on the days of treatment. The statistical significance is indicated by p <0.001.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
This text provides information on the change from baseline in IPSS Total Symptom Score during Trial 3 related to a medical treatment. The data seems to be presented in a table or figure format for evaluation.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
This text provides information about the mean change from baseline in peak urine flow rate over 5 days of treatment in Trial 2.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
This text provides information about the mean change from baseline in peak urine flow rate during a clinical trial, specifically Trial 3. It appears to be related to a medical study or research project.*
FDA Label Image

Chemical Structure (Alfuzosin Str)

Chemical Structure (Alfuzosin Str)
Not available.*
FDA Label Image

Label (Lbl713352578)

Label (Lbl713352578)
Each extended-release tablet contains Alfuzosin Hydrochloride, USP 10 mg. This medication needs to be stored at 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). It must be kept away from children, protected from light and moisture, and dispensed in a tight, light-resistant container as defined in the USP. The tablets come in a pack of 30, repackaged by Bryant Ranch Prepack, Inc., and manufactured by Aurobindo Pharma Limited.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.